Cross-cultural Adaptation of the Safety Assessment Scale for Elderly People With a Major Neurocognitive Disorder Living at Home.
NCT ID: NCT05485090
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
116 participants
OBSERVATIONAL
2022-08-01
2023-12-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This scale is a risk assessment grid for accidents and injuries at home for elderly people with major neurocognitive disorders, available in English and French (Canadian). There are two versions:
* The short version is used for screening. A score of 11 to 14 indicates a moderate risk of injury, while a score ≥ 15 indicates a high risk of injury;
* The long version is used for in-depth assessment when the score on the short version indicates a moderate or high risk of injury. The questionnaire is divided into nine sections:
1. Caregiver and environment, 2/smoking, 3/fire and burns, 4/nutrition, 5/food poisoning and toxic substances, 6/medication and health problems, 7/wandering and adaptation to temperature changes, 8/trauma, and 9/driving.
The short version includes some of the questions from sections 1 to 7 of the long version.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cognitive Prefrail and Frailty, and Motoric Cognitive Risk Syndrome: Prevalence and Association With Incident Adverse Health Events
NCT04275817
Risk Factors for Falls and Neurocognitive Disorders CLSA
NCT03628768
Home-based Cognitive Monitoring in MCI
NCT04350801
Risk Factors for Falls and Fall-related Injuries Associated With Mild Neurocognitive Disorders
NCT03978650
The "Motoric Cognitive Risk" Syndrome in the Canadian Population
NCT03679026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The other objectives of this study are to assess the test-retest reliability and the inter-rater reliability of the translated scale and to evaluate the internal consistency of the long version of the translated scale.
Conduct of research:
Caregivers of patients with major neurocognitive disorders included in the study will complete the adapted scale with an investigator. A pre-test phase will be carried out with 10 caregivers: the caregivers will complete the questionnaire only once with an investigator.
After this phase, the translated Safety Assessment Scale will be corrected if there are difficulties in understanding certain words or sentences. The new scale will then be evaluated on two cohorts of 53 caregivers (cohort 1: caregivers will complete the adapted scale twice with the same investigator; cohorte 2: caregivers will complete the adapted scale twice with two different investigators).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test Phase : Test-Retest Reliability
Caregivers will complete the questionnaire twice with the same investigator. The interval between the two questionnaires is 3 to 10 days.
Questionnaire : Adapted Safety Assessment Scale
Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.
Test Phase : Inter-rater Reliability
Caregivers will complete the questionnaire twice with two different investigators. The interval between the two questionnaires is 3 to 10 days.
Questionnaire : Adapted Safety Assessment Scale
Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaire : Adapted Safety Assessment Scale
Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with a major neurocognitive disorder (Diagnostic and Statistical Manual of Mental Disorders, fifth version) :
* evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, social cognition) based on : a concern by the individual, a knowledgeable informant, or the clinician about a significant decline in cognitive function ; and a deficit in cognitive performance, preferably documented by standardized neuropsychological tests or by another quantified clinical assessment
* the cognitive deficits interfere with independence in daily activities. At least, assistance should be required with complex instrumental activities of daily living, such as paying bills or managing medications.
* the cognitive deficits do not occur exclusively in the context of a delirium.
* the cognitive deficits are not better explained by another mental disorder (e.g., major depressive disorder, schizophrenia).
* Patient with at least one caregiver:
* reliable (no suspicion of cognitive or psychiatric disorders and/or inappropriate behavior such as manipulation or abuse)
* able to answer the questionnaire (i.e., knows the patient's lifestyle)
* No objection to participating in the study from the caregiver and the patient (if able to understand the study)
* No objection to guardian participation for patients under guardianship or curatorship
Exclusion Criteria
* Bedridden patients
* For hospitalized patients, no planned return home
* Patients under judicial protection
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clémence BONNOT, Occupational Therapist
Role: PRINCIPAL_INVESTIGATOR
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GHRMSA
Mulhouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Link to the article
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A02428-33
Identifier Type: OTHER
Identifier Source: secondary_id
GHRMSA 1209
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.